Perioperative nivolumab before nephrectomy followed by adjuvant nivolumab did not improve recurrence-free survival versus surgery only followed by surveillance in patients with high-risk renal cell carcinoma.
Perioperative nivolumab before nephrectomy followed by adjuvant nivolumab did not improve recurrence-free survival versus surgery only followed by surveillance in patients with high-risk renal cell carcinoma.
For Additional News from OncWeekly – Your Front Row Seat To The Future of Cancer Care –
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Privacy Policy